RxDoctor Payments Data

Molly Holt, APRN

Family · New London, CTNPI 1265689855

Payments from drug & device makers

$897in general payments, 2019–2025

Across 38 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$476
  • GSK$223
  • Regeneron Healthcare Solutions, Inc.$106
  • Boehringer Ingelheim$57
  • Amgen$18
  • AstraZeneca$18

What the payments were for

  • Food & beverage$897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$897 in reported general payments places this provider in the 70th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$12,905
Medicare patients
130
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter657$485,639
Breo ElliptaFluticasone/Vilanterol188$80,947
TezspireTezepelumab-Ekko11$49,160
Spiriva RespimatTiotropium Bromide75$38,752
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr70$34,370
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$33,414
Incruse ElliptaUmeclidinium Bromide71$29,565
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate110$27,640
Arnuity ElliptaFluticasone Furoate75$22,324
Spiriva HandihalerTiotropium Bromide29$18,119
SymbicortBudesonide/Formoterol Fumarate56$13,877
XolairOmalizumab12$12,214
Advair HfaFluticasone Propion/Salmeterol27$10,755
Albuterol Sulfate HfaAlbuterol Sulfate340$10,148
Combivent RespimatIpratropium/Albuterol Sulfate21$9,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$223$652,8451,061 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$18$96,452107 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat$57$48,67996 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,596 family providers in Connecticut.

Other family in New London

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →